Key result
Inhibition of the renin-angiotensin-aldosterone system and plasminogen activator-inhibitor-1 can prevent progression and potentially induce regression of glomerulosclerosis.
Why the study?
This article explores the interaction between the renin-angiotensin-aldosterone system and plasminogen activator-inhibitor-1 and its potential significance in progressive renal disease pathogenesis and renal sclerosis remodeling.
This review highlights the potential for regressing glomerulosclerosis through targeted inhibition of the renin-angiotensin-aldosterone system and its downstream effects on PAI-1 and extracellular matrix degradation.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open translation of dual RAAS/PAI-1 inhibition to human glomerulosclerosis.
The role of the renin-angiotensin system in hypertension and end-organ damage has long been recognized. Angiotensin l converting enzyme inhibitors are superior to other antihypertensive agents in protecting the kidney against progressive deterioration, even in normotensive persons. Likewise, angiotensin II type 1 receptor antagonists improve or even reverse glomerulosclerosis in rat animal models. These findings suggest that Angiotensin II has nonhemodynamic effects in progressive renal disease. The renin-angiotensin system is now recognized to be linked to the induction of plasminogen activator-inhibitor-1, possibly via the AT4 receptor, thus promoting both thrombosis and fibrosis. Interactions of the renin-angiotensin system with aldosterone and bradykinin may impact both blood pressure and tissue injury. The beneficial effect on renal fibrosis of inhibiting the renin-angiotensin system likely reflects the central role that angiotensin has in regulating renal function and structure by its various actions. This article explores the renin-angiotensin-aldosterone system with plasminogen activator-inhibitor-1 interaction and the potential significance of these interactions in the pathogenesis of progressive renal disease and remodeling of renal sclerosis.
No takes yet. Share an insight, caveat, or question.
Stoian et al. (2020) conducted a review in Glomerulosclerosis. Renin-angiotensin-aldosterone system inhibitors was evaluated. Inhibition of the renin-angiotensin-aldosterone system and plasminogen activator-inhibitor-1 can prevent progression and potentially induce regression of glomerulosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: